Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK521 in Advanced Solid Tumors
NCT07657416Phase 1Not yet recruiting
- Sponsor
- Base Therapeutics
- Start
- Jan 2027
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of NK521 in hepatocellular carcinoma (HCC), ovarian cancer and malignant ascites (2 arms), sponsored by Base Therapeutics. Primary endpoint: Incidence of Treatment-Emergent Adverse Events and dose-limiting toxicities at 24 months. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
NK521
03
Conditions
hepatocellular carcinoma (HCC)ovarian cancermalignant ascites
Beyond the preview
Go deeper on NCT07657416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07657416.